Detalhe da pesquisa
1.
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Oncotarget
; 14: 57-70, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36702329